Abstract:Abstract Introduction Bronchiectasis (BE) is characterized by recurrent infections and dilated airways and has been associated with recurrent exacerbations and hospitalizations affecting quality of life. Approximately 40-60% of patients with BE have concomitant OSA, with an increased AHI (apnea-hypopnea index) in BE patients with Pseudomonas infections. We hypothesize that patients with BE are less tolerant of PAP therapies, contributing to worsening quality of life related to either condition. We aim to determine differences in PAP adherence and treatment response in patients with BE and OSA compared with a matched OSA-control group. Methods A retrospective cohort analysis was conducted on adult patients evaluated at Mayo Clinic Center for Sleep Medicine between January 2000 to December 2020. Inclusion criteria were patients greater than 18 years old diagnosed with BE and OSA per current guidelines and were prescribed PAP therapy. Control OSA patients were matched to BE/OSA patients by gender, BMI, and AHI severity. Exclusion criteria included cystic fibrosis, hospice enrollment, active lung transplant evaluation, and lack of sleep clinic follow-up. Follow-up visits determined PAP compliance and change in quality-of-life metrics over 3 years. Results We compared 50 patients with BE/OSA with 74 OSA matched controls. The etiology of BE in these cases included COPD (32%) or other etiologies (34%). Baseline characteristics were not statistically different in gender, BMI, and AHI severity across groups. Median treatment follow-up for the BE/OSA group was 3 years [IQR 2 to 4]. Importantly, there was no statistically significant difference in PAP adherence in patients with BE/OSA compared to OSA controls regardless of etiology of BE, but these patients more often required supplemental oxygen therapy. Interestingly, there was a statistically significant increase in MRC and decrease in FEV1 over time in BE patients compliant to therapy. Conclusion There was no significant difference in baseline OSA characteristics, treatment response, and PAP adherence, except for need of oxygen supplementation in BE patients with OSA compared with matched non-BE OSA controls. FEV1 values decreased, and dyspnea score increased in BE patients compliant to PAP therapy; however, future larger studies should include longer-term follow-up to further assess the impact of PAP therapy on BE progression and outcomes. Support (if any)

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper explored the effects of exogenous melatonin on the blood glucose, insulin, and C - peptide dynamics in individuals with type 2 diabetes risk variants in the MTNR1B gene. Specifically, the study aimed to answer the following questions: 1. **Does exogenous melatonin affect blood - glucose tolerance, insulin sensitivity, and β - cell function?** 2. **Is this effect more significant in at - risk individuals carrying the G - allele of the MTNR1B gene?** ### Research background Genome - wide association studies have found that the common variant rs10830963 in the MTNR1B gene is associated with an increased risk of type 2 diabetes. This finding has led to widespread attention on the role of melatonin in blood - glucose control. However, the specific mechanism of this association remains unclear. Therefore, the researchers designed a double - blind, randomized, cross - over trial to explore the effects of exogenous melatonin on blood - glucose metabolism indicators in individuals with different genotypes. ### Methods - **Participants**: 21 healthy participants of European ancestry, of which 10 were MTNR1B risk carriers (mean age ± standard deviation: 29 ± 10 years; BMI: 24.4 ± 2.6 kg/m²; 5 females), and 11 were non - carriers (32 ± 10 years; 22.5 ± 3.0 kg/m²; 3 females). - **Experimental design**: Each participant received 5 mg of oral melatonin or a placebo on two non - consecutive days in a highly controlled 5 - day laboratory protocol. Blood levels after melatonin administration were confirmed by hourly blood sampling. - **Detection methods**: Insulin sensitivity (SI), β - cell function, and the disposition index (DI, the product of insulin secretion and sensitivity) were evaluated using a modified frequently sampled intravenous glucose tolerance test (FSIGT) combined with minimal model analysis. ### Results - **Incremental area under the blood - glucose curve (iAUC180min)**: There were significant differences in the effects of melatonin and placebo between different genotypes (Pinteraction = 0.005). In carriers, iAUC180min increased by 11.7% (95% CI 3.1% - 20.2%, P = 0.03) after melatonin treatment, while there was no significant change in non - carriers. - **Incremental area under the insulin curve (iAUC20min)**: There were significant differences in the effects of melatonin and placebo between different genotypes (Pinteraction = 0.03). In carriers, iAUC20min decreased by 25.2% (4.4% - 41.2%, P = 0.06) after melatonin treatment, while there was no significant change in non - carriers. - **Incremental area under the C - peptide curve (iAUC20min)**: There were significant differences in the effects of melatonin and placebo between different genotypes (Pinteraction = 0.03). In carriers, iAUC20min decreased by 19.2% (4.9% - 31.2%, P = 0.04) after melatonin treatment, while there was no significant change in non - carriers. - **First - phase insulin secretion**: Melatonin had a significant effect on first - phase insulin secretion in carriers (Pinteraction = 0.001), decreasing it by 40.0% (27.6% - 50.3%, P < 0.0001), while there was no significant change in non - carriers. ### Conclusions Exogenous melatonin significantly impairs blood - glucose tolerance and β - cell function in MTNR1B risk carriers, but has no significant effect on non - carriers. These data suggest that first - phase insulin secretion plays an important role in mediating the effect of melatonin on blood - glucose control and its interaction with the MTNR1B genotype.

0888 Characterization and Outcomes in Patients with Bronchiectasis and Obstructive Sleep Apnea with PAP Therapy

Positive Airway Pressure Adherence and Health Care Resource Utilization in Patients With Obstructive Sleep Apnea and Heart Failure With Reduced Ejection Fraction

Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis

Air pollution, weather and positive airway pressure treatment adherence in adults with sleep apnea: a retrospective community‐based repeated‐measures longitudinal study

Correlation between positive airway pressure and medication adherence: the healthy user effect

0569 Breathing Easy Together: How Positive Airway Pressure Adherence Benefits Both Patients and Partners

Effect of telemonitoring and as-needed patient support on positive airway pressure therapy adherence

A comparison of two obesity-related hypoventilation disorders: Impact on sleep, quality of life and neurocognitive outcomes and the effects of positive airway pressure therapy

0578 Feasibility and Preliminary Efficacy of WePAP, a Dyadic Transdiagnostic Intervention

Effects of Positive Airway Pressure on Cardiorespiratory Fitness in Patients with Concomitant Obstructive Sleep Apnea and Cardiovascular Disease

0538 Healthcare Resource Utilization in Treated Obstructive Sleep Apnea Patients with Comorbid Insomnia

0905 Effects of Benign Prostatic Hyperplasia Surgery on Positive Airway Pressure Therapy Compliance in Sleep Apnea

Effect of compliance to continuous positive airway pressure on exacerbations, lung function and symptoms in patients with chronic obstructive pulmonary disease and obstructive sleep apnea (overlap syndrome)

Sleepiness, fatigue, anxiety and depression in Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea - Overlap - Syndrome, before and after continuous positive airways pressure therapy

Impact of PAP on the gut microbiome in OSA: A pilot study

0543 The Utility of the PAP NAP for Increasing Patient Utilization of Positive Airway Pressure Therapy

Efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease and obstructive sleep apnea; a randomized controlled trial

Evaluation of Treatment Outcomes and Quality of Life in Patients with Obstructive Sleep Apnea Receiving Oral Appliance Therapy

Positive airway pressure adherence and subthreshold adherence in posttraumatic stress disorder patients with comorbid sleep apnea

Healthcare resource utilisation and costs in patients with treated obstructive sleep apnea

0585 PAP Therapy Impact on Bariatric Surgery Complications: A 30-Day Pre-Operative Evaluation